TransCode Therapeutics (RNAZ) Competitors $1.12 +0.35 (+45.45%) Closing price 03/21/2025 04:00 PM EasternExtended Trading$1.09 -0.03 (-3.04%) As of 03/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RNAZ vs. PTIX, PBLA, CYCC, GRTX, VINC, ZVSA, KRBP, ATXI, VCNX, and GLMDShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Protagenic Therapeutics (PTIX), Panbela Therapeutics (PBLA), Cyclacel Pharmaceuticals (CYCC), Galera Therapeutics (GRTX), Vincerx Pharma (VINC), ZyVersa Therapeutics (ZVSA), Kiromic BioPharma (KRBP), Avenue Therapeutics (ATXI), Vaccinex (VCNX), and Galmed Pharmaceuticals (GLMD). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Protagenic Therapeutics Panbela Therapeutics Cyclacel Pharmaceuticals Galera Therapeutics Vincerx Pharma ZyVersa Therapeutics Kiromic BioPharma Avenue Therapeutics Vaccinex Galmed Pharmaceuticals Protagenic Therapeutics (NASDAQ:PTIX) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment. Do analysts recommend PTIX or RNAZ? TransCode Therapeutics has a consensus price target of $20.00, suggesting a potential upside of 1,685.71%. Given TransCode Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TransCode Therapeutics is more favorable than Protagenic Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagenic Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor PTIX or RNAZ? TransCode Therapeutics received 15 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformProtagenic TherapeuticsN/AN/ATransCode TherapeuticsOutperform Votes1593.75% Underperform Votes16.25% Is PTIX or RNAZ more profitable? Protagenic Therapeutics' return on equity of -308.97% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protagenic TherapeuticsN/A -308.97% -228.73% TransCode Therapeutics N/A -649.03%-281.34% Does the media favor PTIX or RNAZ? In the previous week, Protagenic Therapeutics' average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score. Company Overall Sentiment Protagenic Therapeutics Neutral TransCode Therapeutics Neutral Which has higher valuation and earnings, PTIX or RNAZ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagenic TherapeuticsN/AN/A-$5M-$1.27-0.22TransCode TherapeuticsN/AN/A-$18.55MN/AN/A Do insiders & institutionals believe in PTIX or RNAZ? 8.0% of Protagenic Therapeutics shares are held by institutional investors. 35.0% of Protagenic Therapeutics shares are held by insiders. Comparatively, 2.8% of TransCode Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, PTIX or RNAZ? Protagenic Therapeutics has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. SummaryProtagenic Therapeutics and TransCode Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Remove Ads Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$780,000.00$7.11B$5.71B$8.13BDividend YieldN/A2.73%4.41%4.07%P/E RatioN/A6.4224.3118.97Price / SalesN/A235.83397.7491.49Price / CashN/A65.6738.1634.64Price / Book0.016.737.104.43Net Income-$18.55M$142.68M$3.19B$247.22M7 Day Performance44.00%3.09%1.95%1.95%1 Month Performance-86.12%-1.56%3.54%-6.11%1 Year Performance-99.85%-5.60%14.27%3.65% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics1.6387 of 5 stars$1.12+45.5%$20.00+1,685.7%-99.8%$780,000.00N/A0.009Gap UpHigh Trading VolumePTIXProtagenic Therapeutics0.4848 of 5 stars$0.28+6.1%N/A-80.5%$2.03MN/A-0.222Positive NewsGap DownPBLAPanbela TherapeuticsN/A$0.41+9.2%N/A-50.4%$1.97MN/A-0.016Upcoming EarningsGap UpCYCCCyclacel Pharmaceuticals1.9105 of 5 stars$0.30+2.6%$11.00+3,508.9%-85.5%$1.92M$74,000.00-0.0314Gap UpGRTXGalera TherapeuticsN/A$0.04+2.9%N/A-86.2%$1.90MN/A-0.1030Upcoming EarningsGap UpVINCVincerx Pharma2.4849 of 5 stars$0.83+0.8%$40.00+4,725.1%-99.4%$1.86MN/A-0.0460Upcoming EarningsZVSAZyVersa Therapeutics2.6671 of 5 stars$0.79+0.0%$120.00+15,089.9%-90.9%$1.85MN/A0.002Upcoming EarningsKRBPKiromic BioPharmaN/A$1.17-2.3%N/A-88.9%$1.84MN/A-0.3460News CoverageGap DownATXIAvenue Therapeutics2.6737 of 5 stars$0.89+12.4%N/A-97.0%$1.82MN/A0.054Upcoming EarningsVCNXVaccinexN/A$0.66-10.8%N/A-93.1%$1.72M$388,000.00-0.0140News CoverageGap DownGLMDGalmed Pharmaceuticals1.0222 of 5 stars$2.50+44.8%N/A-40.6%$1.61MN/A-0.1520Analyst ForecastShort Interest ↑News CoverageGap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Protagenic Therapeutics Competitors Panbela Therapeutics Competitors Cyclacel Pharmaceuticals Competitors Galera Therapeutics Competitors Vincerx Pharma Competitors ZyVersa Therapeutics Competitors Kiromic BioPharma Competitors Avenue Therapeutics Competitors Vaccinex Competitors Galmed Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAZ) was last updated on 3/22/2025 by MarketBeat.com Staff From Our PartnersTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
